MCID: HMN010
MIFTS: 61

Hemangioma

Categories: Blood diseases, Cancer diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Hemangioma

MalaCards integrated aliases for Hemangioma:

Name: Hemangioma 12 74 29 54 6 43 15 17 71
Hemangiomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:255
ICD9CM 34 228.00
MeSH 43 D006391
NCIt 49 C3085
SNOMED-CT 67 2099007 400210000
ICD10 32 D18.0
UMLS 71 C0018916

Summaries for Hemangioma

Disease Ontology : 12 A cardiovascular organ benign neoplasm that has material basis in endothelial cells that line blood vessels and is characterised by increased number of normal or abnormal vessels filled with blood.

MalaCards based summary : Hemangioma, also known as hemangiomas, is related to hemangioma, capillary infantile and cavernous hemangioma. An important gene associated with Hemangioma is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs parecoxib and Sufentanil have been mentioned in the context of this disorder. Affiliated tissues include Heart, liver and bone, and related phenotypes are Decreased sensitivity to paclitaxel and cardiovascular system

Wikipedia : 74 A hemangioma or haemangioma is a usually benign vascular tumor derived from blood vessel cell types. The... more...

Related Diseases for Hemangioma

Diseases in the Hemangioma family:

Malignant Hemangioma Acquired Hemangioma
Familial Hemangioma Congenital Hemangioma

Diseases related to Hemangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1308)
# Related Disease Score Top Affiliating Genes
1 hemangioma, capillary infantile 35.1 MYH9 KDR FLT4 ANTXR1
2 cavernous hemangioma 34.6 VEGFA PECAM1 NKX2-1 KRIT1 KDR FGF2
3 glomeruloid hemangioma 34.6 VEGFA PECAM1 CD34
4 hemangioma of liver 34.5 VHL KRIT1
5 skin hemangioma 34.4 SLC2A1 RPL5 PECAM1
6 cerebral cavernous malformations 34.3 TEK PTEN PECAM1 KRIT1 KDR
7 skin epithelioid hemangioma 34.3 PECAM1 CD34
8 intramuscular hemangioma 34.3 TEK PECAM1 CD34
9 central nervous system hemangioma 34.3 VEGFA PECAM1 CD34
10 acquired hemangioma 34.2 PROX1 PECAM1 PDPN
11 hemangioma of spleen 34.2 PECAM1 CD34
12 capillary hemangioma 34.1 VHL VEGFA TEK SLC2A1 PROX1 PECAM1
13 hobnail hemangioma 34.1 PECAM1 PDPN FLT4 CD34
14 breast hemangioma 34.1 PECAM1 CD34
15 arteriovenous malformation 34.1 VEGFA TEK PTEN KRAS
16 histiocytoid hemangioma 33.8 PECAM1 CD34
17 klippel-trenaunay-weber syndrome 33.5 TEK KRIT1 FLT4
18 hemangioendothelioma 33.5 FLT4 CD34
19 epithelioid hemangioendothelioma 33.5 VEGFA KDR ACTC1
20 pyogenic granuloma 33.2 TEK KRAS CD34 ACTC1
21 liver angiosarcoma 32.9 PECAM1 KRAS
22 kaposiform hemangioendothelioma 32.9 PROX1 PECAM1 KDR FLT4 CD34
23 kaposi sarcoma 31.5 VEGFA KDR FLT4 FGF2
24 intravascular papillary endothelial hyperplasia 31.4 VEGFA ACTC1
25 teratoma 31.3 PTEN NKX2-1 KRAS ACTC1
26 meningioma, familial 31.3 VEGFA PTEN PECAM1 CD34
27 varicose veins 31.3 VEGFA KDR FGF2
28 angiosarcoma 31.3 VEGFA TEK PROX1 PECAM1 PDPN KRAS
29 retinal vascular disease 31.2 VEGFA TEK KDR FGF2
30 adenocarcinoma 31.1 VEGFA PTEN NKX2-1 KRAS KDR
31 pericardial effusion 31.1 VEGFA FGF2 CD34
32 sarcoma 31.1 VEGFA KRAS KDR FLT4 FGF2 ACTC1
33 vascular cancer 31.1 VEGFA PROX1 PECAM1 PDPN KDR FLT4
34 exanthem 31.1 VEGFA KRAS KDR
35 spindle cell sarcoma 31.1 VEGFA CD34 ACTC1
36 papilloma 31.0 VEGFA PTEN KRAS ACTC1
37 neovascular glaucoma 31.0 VEGFA KDR FGF2
38 lymphangioma 31.0 VEGFA PROX1 PECAM1 PDPN KRAS KDR
39 microvascular complications of diabetes 5 31.0 VEGFA TEK SLC2A1 KDR FGF2
40 hemifacial spasm 31.0 VEGFA FLT4
41 hemangiopericytoma, malignant 30.9 PECAM1 CD34 ACTC1
42 cystic teratoma 30.9 PTEN NKX2-1 KRAS
43 hereditary lymphedema i 30.9 PROX1 PDPN FLT4
44 intussusception 30.8 VEGFA TEK PECAM1 KDR FLT4 FGF2
45 leiomyosarcoma 30.8 VEGFA PECAM1 ACTC1
46 renal cell carcinoma, nonpapillary 30.8 VHL VEGFA TEK SLC2A1 PTEN PECAM1
47 macular degeneration, age-related, 1 30.8 VEGFA TEK PECAM1 KDR FLT4 FGF2
48 vascular disease 30.8 VEGFA TEK PECAM1 KRIT1 KDR FGF2
49 exudative vitreoretinopathy 1 30.8 VEGFA TEK PECAM1 KDR FGF2
50 myeloma, multiple 30.8 VEGFA PTEN KRAS KDR FGF2 CD34

Graphical network of the top 20 diseases related to Hemangioma:



Diseases related to Hemangioma

Symptoms & Phenotypes for Hemangioma

GenomeRNAi Phenotypes related to Hemangioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased sensitivity to paclitaxel GR00112-A-0 8.32 PTEN

MGI Mouse Phenotypes related to Hemangioma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 ACTC1 ANTXR1 FGF2 FLT4 KDR KRAS
2 cellular MP:0005384 10.45 ACTC1 ANTXR1 CD34 DIO3 FGF2 KDR
3 growth/size/body region MP:0005378 10.45 ACTC1 ANTXR1 DIO3 FLT4 KDR KRAS
4 homeostasis/metabolism MP:0005376 10.45 ACTC1 CD34 DIO3 FGF2 FLT4 KDR
5 mortality/aging MP:0010768 10.41 ACTC1 ANTXR1 DIO3 FGF2 FLT4 KDR
6 hematopoietic system MP:0005397 10.31 CD34 FGF2 KDR KRAS MYH9 PDPN
7 immune system MP:0005387 10.29 ANTXR1 CD34 FLT4 KDR KRAS MYH9
8 embryo MP:0005380 10.26 FLT4 KDR KRAS KRIT1 MYH9 PTEN
9 muscle MP:0005369 10.25 ACTC1 FGF2 FLT4 KDR KRAS KRIT1
10 digestive/alimentary MP:0005381 10.22 FLT4 KRAS NKX2-1 PDPN PECAM1 PROX1
11 integument MP:0010771 10.15 CD34 FLT4 KDR KRAS KRIT1 PDPN
12 nervous system MP:0003631 10.15 ACTC1 FGF2 KDR KRAS KRIT1 MYH9
13 liver/biliary system MP:0005370 10.13 DIO3 FLT4 KDR KRAS PECAM1 PROX1
14 neoplasm MP:0002006 10.06 ANTXR1 CD34 FGF2 KRAS KRIT1 NKX2-1
15 normal MP:0002873 10 ACTC1 FLT4 KDR KRAS MYH9 NKX2-1
16 no phenotypic analysis MP:0003012 9.92 ANTXR1 FLT4 KDR KRAS MYH9 NKX2-1
17 respiratory system MP:0005388 9.76 KDR KRAS NKX2-1 PDPN PECAM1 PROX1
18 skeleton MP:0005390 9.65 ANTXR1 FGF2 KDR KRAS NKX2-1 PDPN
19 vision/eye MP:0005391 9.32 FGF2 KDR KRAS KRIT1 MYH9 PROX1

Drugs & Therapeutics for Hemangioma

Drugs for Hemangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
parecoxib Approved Phase 4 198470-84-7
2
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
3
Captopril Approved Phase 4 62571-86-2 44093
4 Ethiodized oil Approved, Investigational Phase 4 8008-53-5
5
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
6
Propranolol Approved, Investigational Phase 4 525-66-6 4946
7 Cyclooxygenase Inhibitors Phase 4
8 Cyclooxygenase 2 Inhibitors Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Antirheumatic Agents Phase 4
11 Anti-Inflammatory Agents, Non-Steroidal Phase 4
12 Polymethyl Methacrylate Phase 4
13
protease inhibitors Phase 4
14 Angiotensin-Converting Enzyme Inhibitors Phase 4
15 HIV Protease Inhibitors Phase 4
16 Calcineurin Inhibitors Phase 4
17 Vasodilator Agents Phase 4
18
Atenolol Approved Phase 3 29122-68-7 2249
19
Nadolol Approved Phase 3 42200-33-9 39147
20
Acebutolol Approved, Investigational Phase 3 37517-30-9 1978
21 Gastrointestinal Agents Phase 3
22 Antiemetics Phase 3
23 Neuroprotective Agents Phase 3
24 Protective Agents Phase 3
25 Sympatholytics Phase 3
26 Adrenergic beta-1 Receptor Antagonists Phase 3
27 Sympathomimetics Phase 3
28
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
29
Terlipressin Approved, Investigational Phase 2 14636-12-5 72081
30
Ipratropium Approved, Experimental Phase 2 60205-81-4, 22254-24-6 43232 657309
31
Glucagon Approved Phase 2 16941-32-5
32
Atropine Approved, Vet_approved Phase 2 51-55-8, 5908-99-6 174174
33
Isoproterenol Approved, Investigational Phase 2 7683-59-2 3779
34
Betamethasone Approved, Vet_approved Phase 2 378-44-9 9782
35 Strawberry Approved Phase 2
36
Bosentan Approved, Investigational Phase 2 147536-97-8 104865
37
Norflurane Approved, Experimental Phase 2 811-97-2
38
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
39
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
40
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
41
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
42 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
43
Atorvastatin Approved Phase 1, Phase 2 134523-00-5 60823
44
tannic acid Approved Phase 2 1401-55-4
45
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
46
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
47
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
48
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
49
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
50
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 A Randomized, Phase IV Study Exploring the Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy Unknown status NCT02204878 Phase 4 Parecoxib Sodium
2 The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma Completed NCT01908972 Phase 4 Prednisolone;Propranolol
3 Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2) Completed NCT00749086 Phase 4
4 Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma Recruiting NCT04288700 Phase 4 oral propranolol;Oral Captopril;intralesional propranolol injection;topical Timolol maleate 0.5% eye drops
5 Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma:A Prospective, Randomized Open Trial Recruiting NCT04077515 Phase 4 Sirolimus(0.8mg/m2);Sirolimus(0.7mg/m2)
6 Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain Recruiting NCT03181984 Phase 4 Hemoporfin
7 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (7-14 Years Old) With Port-wine Stain Recruiting NCT03125057 Phase 4 Hemoporfin PDT
8 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
9 Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
10 Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma Not yet recruiting NCT04406870 Phase 4 Sirolimus Oral Product;propranolol
11 A Pilot Study of Hemoporfin Photodynamic Therapy in Children (2-7 Years Old) With Port-wine Stain Not yet recruiting NCT04106258 Phase 4 Hemoporfin PDT
12 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
13 Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital Unknown status NCT01685398 Phase 3 0.5% timolol maleate eye drop;Normal saline
14 Blood Oxygen Level Dependent fMRI Navigation for Function Protection in Intracranial Arteriovenous Malformation Surgery: a Multicenter Prospective Randomized Controlled Single Blind Clinical Trial Unknown status NCT01758211 Phase 3
15 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3 Timolol + LCP
16 A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double Blind). Completed NCT01056341 Phase 2, Phase 3 Propranolol;Placebo
17 The Efficacy and Safety of Intravenous Pulse Steroids Compared to Standard Oral Steroids in the Treatment of Problematic Hemangiomas in Infants: A Randomized Controlled Trial Completed NCT00312520 Phase 3 prednisolone;methylprednisolone
18 Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma Completed NCT02342275 Phase 3 Propranolol;Atenolol
19 A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation Completed NCT01677624 Phase 3
20 Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction Completed NCT03518398 Phase 3
21 A Randomized Trial of Unruptured Brain Arteriovenous Malformations Completed NCT00389181 Phase 3
22 CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial. Recruiting NCT02332408 Phase 3
23 Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas Recruiting NCT03237637 Phase 3 oral propranolol;oral atenolol
24 Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial Active, not recruiting NCT02505971 Phase 3 Nadolol;Propranolol
25 Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence Not yet recruiting NCT02962947 Phase 2, Phase 3 Propranolol;Placebo
26 Study of the Efficacy of Propranolol for the Management of Epistaxis in Hereditary Hemorrhagic Telangiectasia Patients Not yet recruiting NCT04113187 Phase 3 Propranolol treatment;Placebo
27 Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma Terminated NCT01743885 Phase 3 Acebutolol;Propanolol
28 Double Blind, Randomised, Placebo-controlled Study of Propranolol in Infantile Capillary Hemangiomas Terminated NCT00744185 Phase 2, Phase 3 propranolol treatment;placebo treatment
29 Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced Computed Tomography and/or Magnetic Resonance Imaging Using Sonazoid Withdrawn NCT02651090 Phase 3 Sonazoid
30 A Multicenter, 3-Arm, Open-Label, Phase Ⅱa Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Unknown status NCT03033524 Phase 2 TTAC-0001
31 Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO) Unknown status NCT02732678 Phase 1, Phase 2 PROPRANOLOL
32 Safety and Efficacy of Propranolol Treatment in Newborns With Retinopathy of Prematurity:a Prospective Cohort Study Unknown status NCT03038295 Phase 2 Propranolol;placebo
33 Topical Timolol Gel for the Treatment of Infantile Hemangiomas Completed NCT02145884 Phase 2 timolol maleate 0.5% gel
34 A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy Completed NCT00601016 Phase 2 Imiquimod 5% cream
35 Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control Completed NCT01010308 Phase 2 Nadolol
36 Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial Completed NCT02731287 Phase 2 Timolol;Placebo
37 A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma Completed NCT01072045 Phase 2 Propranolol;Prednisone
38 Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity (ROP): A Pilot, Randomized and Prospective Study. Completed NCT01238471 Phase 1, Phase 2 propranolol;sucrose 5%
39 Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH) Completed NCT02913612 Phase 2 0.25% Timolol Maleate Gel Forming Solution;0.5% Timolol Maleate Gel Forming Solution
40 A Randomised, Double Blind, Controlled, Multicentre Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo. Completed NCT01512173 Phase 2 propranolol gel;Placebo
41 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Completed NCT02859441 Phase 1, Phase 2 Ranibizumab;E10030
42 Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo Completed NCT02484716 Phase 2 Timolol nasal spray;Placebo nasal spray
43 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding Completed NCT00389935 Phase 2 Thalidomide
44 Phase II Clinical Trial is to Compare Epidermal Temperature Measurements During 1.Laser Treatment at Standard Treatment Energies 2.Cryogen Spray Cooling (CSC) Plus Laser Treatment. 3.Contact Cooling Plus Laser Treatment. Completed NCT00540917 Phase 2
45 Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus Completed NCT00523588 Phase 2
46 U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs) Completed NCT00857662 Phase 2
47 Treatment of Port-wine Stains by Bosentan in Addition to Pulsed Dye Laser (PDL) in Children or Young Adults Who Previously Failed to Respond to PDL Alone: a Monocentric Pilot Study Completed NCT02317679 Phase 2 Bosentan
48 Treatment of Superficial Voluminous Complicated Slow-flow Vascular Malformations With Sirolimus: a Phase 2 Trial in Children Observational-phase Designed Completed NCT02509468 Phase 2 Sirolimus
49 Efficacy Evaluation of Propranolol Treatment of Hepatic Hemangioma Recruiting NCT03633747 Phase 1, Phase 2 Propranolol Hydrochloride
50 An Intra-patient Dose Escalation Study of Propranolol in Patients With Lymphedema Recruiting NCT02595996 Phase 2 Propranolol

Search NIH Clinical Center for Hemangioma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: hemangioma

Genetic Tests for Hemangioma

Genetic tests related to Hemangioma:

# Genetic test Affiliating Genes
1 Hemangioma 29

Anatomical Context for Hemangioma

MalaCards organs/tissues related to Hemangioma:

40
Liver, Bone, Endothelial, Skin, Lung, Brain, Breast
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Hemangioma:
# Tissue Anatomical CompartmentCell Relevance
1 Heart Cardinal Veins Venous Endothelial Cells Affected by disease

Publications for Hemangioma

Articles related to Hemangioma:

(show top 50) (show all 18215)
# Title Authors PMID Year
1
[Sinusoidal hemangioma: Immunohistochemical analysis with glucose transporter 1 (GLUT1) and williams tumor protein 1 (WT1)]. 61 54
20487697 2010
2
Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. 54 61
20237346 2010
3
Differential expression of VEGF121, VEGF165 and VEGF189 in angiomas and squamous cell carcinoma cell lines of the head and neck. 54 61
20393000 2010
4
Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. 61 54
20015661 2010
5
Facial nerve hemangiomas: vascular tumors or malformations? 61 54
20096233 2010
6
[Distribution, GLUT-1 expression and early surgical intervention for infantile hemangioma on the face]. 61 54
20030103 2009
7
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. 54 61
19620773 2009
8
Serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in children with hemangiomas and vascular malformations--preliminary report. 61 54
19689513 2009
9
Treatment of hemangioma by transfection of antisense VEGF gene. 61 54
19513617 2009
10
Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. 61 54
19349369 2009
11
[POEMS syndrome with an isolated lytic lesion and glomeruloid hemangiomas: report of one case]. 54 61
19701559 2009
12
[Expression and significance of basic fibroblast growth factor in infant vascular anomalies]. 61 54
19417990 2009
13
A potential role for notch signaling in the pathogenesis and regulation of hemangiomas. 61 54
19169152 2009
14
Suppressing NFAT increases VEGF signaling in hemangiomas. 61 54
19061833 2008
15
Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. 54 61
18931684 2008
16
Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. 61 54
18814928 2008
17
Solitary pulmonary infantile hemangioma in an infant with atrial septal defect. 54 61
17990917 2008
18
GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. 61 54
18620729 2008
19
Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. 54 61
18671617 2008
20
[Current treatment of infantile hemangiomas: an overview of the literature]. 61 54
18784870 2008
21
Possibilities and potential roles of estrogen in the pathogenesis of proliferation hemangiomas formation. 61 54
18434035 2008
22
Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. 61 54
18535669 2008
23
Treatment with interferon-alpha-2b in children with life-threatening hemangiomas. 54 61
18261103 2008
24
Podoplanin is a useful diagnostic marker for epithelioid hemangioendothelioma of the liver. 54 61
18084256 2008
25
Proliferation hemangiomas formation through dual mechanism of vascular endothelial growth factor mediated endothelial progenitor cells proliferation and mobilization through matrix metalloproteinases 9. 54 61
17888584 2008
26
Lack of expression of podoplanin by microvenular hemangioma. 61 54
18650031 2008
27
Eccrine angiomatous hamartoma with features resembling verrucous hemangioma. 54 61
17997743 2007
28
[Expression and significance of Ang1, Ang2 and receptor Tie2 in hemangioma]. 61 54
18269030 2007
29
Effect of anti-KDR antibody on the proliferation of hemangioma vascular endothelial cells in vitro. 61 54
18060633 2007
30
[Head and neck hemangiomas: how and when to treat]. 54 61
17924011 2007
31
[Differential expression of CD133, Glut-1 in tissues and endothelial cells derived from infantile hemangioma and vascular malformation]. 54 61
17926859 2007
32
[Iodothyronine deiodinases expression in thyroid neoplasias]. 61 54
17891232 2007
33
Placental anomalies in children with infantile hemangioma. 61 54
17845154 2007
34
[The expression and role of glucose transporter-1 in infantile hemangioma]. 54 61
17554865 2007
35
GLUT-1 in oral benign vascular lesions. 61 54
17241430 2007
36
[Expression of PCNA, VEGF and bFGF in endothelial cells of juvenile nasopharyngeal angiofibroma]. 61 54
17285972 2006
37
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. 54 61
16741507 2006
38
Hemangiomas and homeobox gene expression. 61 54
16877932 2006
39
[Delayed disappearance of h-VEGF₁₆₅ mRNA and protein under regulation of hypoxic response element]. 61 54
16786114 2006
40
Vascular complications in Chuvash polycythemia. 54 61
16673284 2006
41
Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence. 54 61
16424896 2006
42
[Role of urinary basic fibroblast growth factor in differentiating hemangiomas from vascular malformation]. 61 54
16635349 2006
43
The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy. 61 54
16500033 2006
44
Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase. 54 61
16037131 2005
45
Transgenic rabbits with increased VEGF expression develop hemangiomas in the liver: a new model for Kasabach-Merritt syndrome. 61 54
16200077 2005
46
Unique association of non-functioning pheochromocytoma, ganglioneuroma, adrenal cortical adenoma, hepatic and vertebral hemangiomas in a patient with a new intronic variant in the VHL gene. 54 61
16483185 2005
47
Hemangiomas of infancy: clinical and biological characteristics. 54 61
16327961 2005
48
Assessment of angiogenic markers in oral hemangiomas and pyogenic granulomas. 54 61
16005715 2005
49
Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. 61 54
15988268 2005
50
Expression patterns of markers for type II pneumocytes in pulmonary sclerosing hemangiomas and fetal lung tissues. 61 54
15974816 2005

Variations for Hemangioma

ClinVar genetic disease variations for Hemangioma:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PTEN NM_000314.7(PTEN):c.675T>G (p.Tyr225Ter)SNV Pathogenic 404162 rs1057520900 10:89717650-89717650 10:87957893-87957893
2 RPL5 NM_000969.5(RPL5):c.74-1G>CSNV Pathogenic 523383 rs1553284997 1:93299101-93299101 1:92833544-92833544
3 46;XY;t(7;13)(p15.3;q14.1)dnTranslocation Pathogenic 267837
4 46;XX;t(4;14)(p15.2;q13)dnTranslocation Likely pathogenic 267892
5 46;XX;ins(3;1)(q23;p22p32)dnTranslocation Likely pathogenic 267804
6 PKD1 NM_001009944.3(PKD1):c.359T>C (p.Ile120Thr)SNV Likely pathogenic 523386 rs1555459345 16:2169115-2169115 16:2119114-2119114
7 ARG2 , RDH11 , RDH12 , VTI1B , ZFYVE26 GRCh37/hg19 14q24.1(chr14:68126321-68269053)x3copy number gain Uncertain significance 635772 14:68110557-68283783
8 46;XY;t(1;4)(q32;q11)Translocation Uncertain significance 268019
9 CSMD3 GRCh37/hg19 8q23.3(chr8:114378494-114450308)copy number loss Benign 523292 8:114378494-114450308

Expression for Hemangioma

Search GEO for disease gene expression data for Hemangioma.

Pathways for Hemangioma

Pathways related to Hemangioma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.75 VHL VEGFA TEK PTEN MYH9 KRAS
2
Show member pathways
13.19 TEK SLC2A1 PTEN MYH9 KRAS KDR
3
Show member pathways
12.84 VEGFA TEK PTEN KRAS KDR FLT4
4 12.67 VHL VEGFA SLC2A1 PTEN KRAS FLT4
5 12.64 VEGFA TEK KRAS KDR FLT4 FGF2
6
Show member pathways
12.56 VEGFA TEK KRIT1 KRAS KDR FLT4
7
Show member pathways
12.41 VEGFA PTEN KRAS KDR FGF2
8
Show member pathways
12.36 VHL VEGFA SLC2A1 PTEN KRAS KDR
9
Show member pathways
12.32 TEK KRAS KDR FLT4 FGF2
10
Show member pathways
12.29 VEGFA MYH9 KDR FLT4 FGF2
11 12.22 VEGFA KRAS KDR FGF2
12
Show member pathways
12.15 TEK PTEN KRAS KDR FLT4
13 12.05 TEK KDR FLT4 FGF2
14 11.98 VEGFA PROX1 KDR FGF2
15 11.87 VHL VEGFA TEK SLC2A1
16
Show member pathways
11.74 VHL VEGFA KDR FLT4
17
Show member pathways
11.73 KRAS KDR FLT4
18 11.71 VEGFA SLC2A1 FGF2
19 11.64 SLC2A1 PTEN KRAS
20 11.51 VHL VEGFA SLC2A1
21 11.5 KDR FGF2 ACTC1
22 11.46 VEGFA KDR FGF2
23 11.42 VEGFA KDR FGF2
24 11.15 VHL VEGFA SLC2A1 KDR
25 11.12 TEK PROX1 PECAM1 PDPN KDR FLT4
26 10.99 VEGFA KRAS KDR FLT4 FGF2
27 10.84 VEGFA TEK KDR FGF2
28
Show member pathways
10.81 VEGFA KDR FLT4

GO Terms for Hemangioma

Cellular components related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.31 VHL VEGFA TEK SLC2A1 RPL5 PECAM1
2 plasma membrane GO:0005886 10.13 TEK SLC2A1 PTEN PECAM1 PDPN MYH9
3 integral component of plasma membrane GO:0005887 9.98 TEK SLC2A1 PECAM1 PDPN KDR FLT4
4 cytoplasm GO:0005737 9.86 VHL VEGFA TEK SLC2A1 RPL5 PTEN
5 cell-cell junction GO:0005911 9.67 TEK SLC2A1 PECAM1 KRIT1
6 focal adhesion GO:0005925 9.65 TEK RPL5 MYH9 KRAS ACTC1
7 apical plasma membrane GO:0016324 9.55 TEK SLC2A1 PTEN PDPN CD34
8 membrane raft GO:0045121 9.1 TEK SLC2A1 PECAM1 PDPN KRAS KDR

Biological processes related to Hemangioma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.21 VEGFA TEK PROX1 PDPN KDR FLT4
2 positive regulation of cell proliferation GO:0008284 10.04 VEGFA PTEN PROX1 KRAS KDR FLT4
3 negative regulation of gene expression GO:0010629 9.99 VHL VEGFA KDR FGF2 CD34
4 positive regulation of cell migration GO:0030335 9.98 VEGFA PECAM1 PDPN KDR
5 positive regulation of gene expression GO:0010628 9.98 VEGFA RPL5 PTEN NKX2-1 KRAS CD34
6 leukocyte migration GO:0050900 9.95 TEK PECAM1 MYH9 CD34
7 cell-cell adhesion GO:0098609 9.94 PECAM1 PDPN MYH9 CD34
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 TEK PTEN KDR FLT4 FGF2
9 regulation of cell shape GO:0008360 9.92 VEGFA PDPN MYH9 KDR
10 positive regulation of MAPK cascade GO:0043410 9.87 TEK KDR FLT4 FGF2
11 negative regulation of apoptotic process GO:0043066 9.86 VHL VEGFA TEK PTEN PDPN KDR
12 positive regulation of kinase activity GO:0033674 9.85 TEK KDR FLT4
13 lung development GO:0030324 9.85 VEGFA PROX1 PDPN NKX2-1
14 positive regulation of angiogenesis GO:0045766 9.85 VEGFA TEK KDR FGF2 CD34
15 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.83 VEGFA KDR FLT4
16 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA KRAS FGF2
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.81 VEGFA KDR FGF2
18 positive regulation of protein phosphorylation GO:0001934 9.8 VEGFA TEK PECAM1 KRAS KDR FLT4
19 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.78 VEGFA KDR FGF2
20 negative regulation of endothelial cell apoptotic process GO:2000352 9.77 TEK KRIT1 KDR
21 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.75 VEGFA KDR FLT4
22 positive regulation of focal adhesion assembly GO:0051894 9.73 VEGFA TEK KDR
23 cell migration involved in sprouting angiogenesis GO:0002042 9.7 VEGFA KDR FGF2
24 endothelial cell differentiation GO:0045446 9.69 PROX1 KDR
25 lymph vessel development GO:0001945 9.69 PROX1 FLT4
26 positive regulation of vasculogenesis GO:2001214 9.69 KDR CD34
27 vascular endothelial growth factor signaling pathway GO:0038084 9.69 VEGFA KDR FLT4
28 positive regulation of positive chemotaxis GO:0050927 9.68 VEGFA KDR
29 positive regulation of protein kinase C signaling GO:0090037 9.68 VEGFA FLT4
30 positive regulation of cellular component movement GO:0051272 9.68 VEGFA PDPN
31 stem cell proliferation GO:0072089 9.67 FGF2 CD34
32 skeletal muscle thin filament assembly GO:0030240 9.67 PROX1 ACTC1
33 sprouting angiogenesis GO:0002040 9.67 VEGFA TEK KDR FLT4
34 paracrine signaling GO:0038001 9.65 FGF2 CD34
35 lymphangiogenesis GO:0001946 9.65 PROX1 PDPN FLT4
36 endothelium development GO:0003158 9.64 KDR CD34
37 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 VEGFA KDR
38 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.62 VEGFA KDR
39 actin-mediated cell contraction GO:0070252 9.61 PDPN ACTC1
40 glomerular endothelium development GO:0072011 9.58 PECAM1 CD34
41 vascular wound healing GO:0061042 9.58 VEGFA KDR CD34
42 positive regulation of endothelial cell migration GO:0010595 9.55 VEGFA TEK PROX1 KDR FLT4
43 positive regulation of endothelial cell proliferation GO:0001938 9.43 VEGFA TEK PROX1 KDR FLT4 FGF2
44 angiogenesis GO:0001525 9.28 VEGFA TEK PTEN PECAM1 MYH9 KRIT1

Molecular functions related to Hemangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor binding GO:0038085 9.26 KDR FLT4
2 vascular endothelial growth factor-activated receptor activity GO:0005021 9.16 KDR FLT4
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 TEK KDR FLT4
4 growth factor binding GO:0019838 8.8 TEK KDR FLT4

Sources for Hemangioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....